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Nieodwracalne uszkodzenia mózgu spowodowane przez metamfetaminę
Utrzymujące się strukturalne uszkodzenia mózgu
Sebastian Moeller 1, Hagen B. Huttner 1, Tobias Struffert 2, Helge H. Müller 3,*
1Friedrich-Alexander-University, Department of Neurology, Erlangen-Nuremberg, Germany
2Friedrich-Alexander-University, Department of Neuroradiology, Erlangen-Nuremberg, Germany
3Medical Campus University, School of Medicine and Health Sciences, University Hospital, Karl-Jaspers-Klinik, Department of
Psychiatry and Psychotherapy, Oldenburg, Germany
A R T I C L E I N F O
Article history:
Received: 15.02.2016
Accepted: 22.02.2016
Available online: 04.03.2016
Keywords:
Methamphetamine
MRI (magnetic resonance imaging)
Structural brain lesions
A B S T R A C T
Methamphetamine is an addictive scene substance usage of which is increasing
rapidly. While methamphetamine often causes neuropsychiatric symptoms like
anxiety, psychosis and hallucinations, reports of structural ongoing cerebral
alterations are rare. We here report a case of this kind of damage caused through
methamphetamine use.
© 2016 Institute of Psychiatry and Neurology. Production and hosting by
Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Słowa kluczowe:
metamfetamina
MRI (obrazowanie metodą rezonansu
magnetycznego)
strukturalne uszkodzenia mózgu
S T R E S Z C Z E N I E
Metamfetamina jest substancja uzależniającą, której używanie gwałtownie
wzrasta. Chociaż wiadomo, że metamfetamina często przyczynia się do
powstawania objawów zaburzeń psychicznych, takich jak niepokój, omamy
i psychozy, to doniesienia dotyczące strukturalnych zmian w mózgu należą do
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substance of rapidly increasing usage. There are an
estimated 10 million users in the US and 35 million
worldwide [1–3]. It is snorted, smoked, or injected, and
quickly crosses the blood-brain barrier because of its
lipophilic character. Crystal meth is more potent than
amphetamine [2]. The drug stimulates dopamine,
norepinephrine, and serotonin transporters on neuro-
nal cell membranes. At higher concentrations, it
crosses membranes independent of transporter bind-
ing. Clinically recognisable symptoms are the typical
“meth mouth”, depression, anxiety, fatigue and an
adrenergic withdrawal syndrome with tachycardia,
hypertension, mydriasis, diaphoresis and psychomo-
tor agitation. The most common psychiatric manifes-
tation is a chronic psychosis [4–6].
We treated a formerly healthy 24-year-old male
patient who presented a sudden onset of visual
hallucinations, anxiety, delusions, paranoia, apraxia
and tachycardia. At first, we assumed a diagnosis of
encephalitis, but after taking the patient's history into
consideration, we discovered that he had been
methamphetamine (crystal meth) dependent for
approximately 4 years. Urine drug screening con-
firmed the crystal meth use (3500 ng/ml). Other
diagnostic work-up including CSF-analyses was
completely unremarkable. The patient had no history
of abusing other substances (verified via extended toxi-
-screening). MRI on admission revealed diffusely
increasedsignal intensity of thewhitematter (Figure 1).
The patient's symptoms and structural findings
persisted over the course of the treatment period of
rzadkości. W artykule przedstawiono przypadek uszkodzenia mózgu spowodo-
wanego przez używanie metamfetaminy.
© 2016 Institute of Psychiatry and Neurology. Production and hosting by
Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Diffuse white matter alterations. Example of typical imaging findings: in FLAIR imaging (Fluid attenuated inversion recovery,
upper row) increased signal intensity of the white matter with extensive involvement of the temporal, frontal/parietal and occipital lobe
is present. The cortex, basal ganglia, brain stem, and cerebellum are not involved. After contrast injection pathologic uptake is not
present (not shown). Diffusion weighted imaging (DWI, lower row) shows high signal intensity at a b-value of 1000 of the white matter
as on corresponding apparent diffusion coefficient (ADC, not shown) maps
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7 months.
Research reports ongoing structural brain alter-
ations with extensive white matter changes in all lobes
are rare and the few examinations suppose crystal
meth to mainly affect the cortex, and hippocampal,
thalamic and hypothalamic structures. Previous
research suggested correlations of crystal meth
exposure and striatal volume [7–9]. However, our
patient presented diffuse white matter injury. The
cortex, basal ganglia, brain stem, and cerebellum were
not affected.
The finding emphasises crystal meth as a substance
capable of causing the remaining cerebral damage
not only within intoxication or during withdrawal.
Because of those permanent severe brain damages,
additional systematic examinations in crystal meth
dependent users are recommended.
Because crystal meth use has increased dramati-
cally worldwide [10], treating physicians should be
aware of the impressive brain alterations that can be
seen on imaging, like those reported here.
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